SPL 2.00% 9.8¢ starpharma holdings limited

Ann: SPL7013 shows potent antiviral activity in RSV, page-3

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 90 Posts.
    lightbulb Created with Sketch. 67
    Progress!
    ”SPL7013 has been formulated into a preventative antiviral nasal spray, VIRALEZE, which is now in the late stages of development and on track to be commercially available in H1 2021, with first launches expected to occur in Europe and other regions to follow”
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.